Search results
Showing 61 to 75 of 183 results for glucose
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
This indicator covers admission rates due to myocardial infarction in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG60
This indicator covers admission rates due to heart failure in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG61
Acute kidney injury: prevention, detection and management (NG148)
This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.
This indicator covers the percentage of patients with non-diabetic hyperglycaemia who have had an HbA1c test or FPG test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM150
This indicator covers admission rates due to angina in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG59
This indicator covers the percentage of patients with diabetes who have had the following care processes performed in the preceding 12 months: BMI measurement, BP measurement, HbA1c measurement, cholesterol measurement, record of smoking status, foot examination, albumin:creatinine ratio, eGFR creatinine measurement. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM74
This indicator covers the establishing and maintaining of a register of all patients with a diagnosis of non-diabetic hyperglycaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM148
This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
This indicator covers the percentage of patients newly diagnosed with non-diabetic hyperglycaemia in the preceding 12 months who have been referred to a Healthier You: NHS Diabetes Prevention Programme for intensive lifestyle advice. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM149
This indicator covers the percentage of patients with diabetes with moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM158
This indicator covers the percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM157